LB-102 for Schizophrenia
(NOVA3 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a medication called LB-102, a new potential drug, to determine its safety and tolerability for people with stable schizophrenia. Schizophrenia is a mental health condition that affects thinking, feeling, and behavior. The trial focuses on patients who have taken oral antipsychotic medication for at least 30 days and maintain stability in their condition. Those with a stable living situation and who manage schizophrenia with existing medications may find this trial suitable. As a Phase 3 trial, it represents the final step before FDA approval, offering a chance to contribute to a potentially groundbreaking treatment.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it does require that you have been taking oral antipsychotic treatment for at least 30 days before joining. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that LB-102 is likely to be safe for humans?
Research has shown that LB-102 is generally well-tolerated. In previous trials, most people with schizophrenia experienced few side effects while taking LB-102. One study found that using LB-102 for 4 weeks was both effective and safe, with most participants not experiencing serious adverse reactions.
Another study confirmed that LB-102 was safe and effective in managing schizophrenia symptoms. Some participants experienced mild side effects, but these did not lead to discontinuation of treatment.
Overall, earlier research indicates that LB-102 has a good safety record, suggesting it might be a safe option for treating schizophrenia, although individual experiences can vary.12345Why do researchers think this study treatment might be promising?
LB-102 is unique because it offers a novel approach to treating schizophrenia by potentially improving upon the safety and efficacy profile of existing medications. Schizophrenia is commonly treated with antipsychotic drugs like risperidone and olanzapine, which often come with significant side effects. LB-102 is a new derivative of amisulpride, designed to provide similar therapeutic benefits with fewer side effects. Researchers are excited about LB-102 because it may offer patients a better quality of life by reducing the adverse effects while maintaining or enhancing the effectiveness in managing symptoms.
What evidence suggests that LB-102 might be an effective treatment for schizophrenia?
Research has shown that LB-102 offers promising results for treating schizophrenia. Studies found that people with acute schizophrenia who took LB-102 experienced significant symptom improvements compared to those who took a placebo, a pill with no active medicine. LB-102 reduced symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS). This indicates that LB-102 can effectively ease schizophrenia symptoms. Additionally, the treatment was generally well-tolerated, causing no severe side effects for most participants. This evidence supports LB-102 as a potentially effective option for managing schizophrenia symptoms.12567
Who Is on the Research Team?
John Kane, MD
Principal Investigator
Northwell Health
Are You a Good Fit for This Trial?
This trial is for adults with stable schizophrenia who are medically healthy, have been on oral antipsychotic medication for at least 30 days, have a BMI between 18 and 40, and live in a stable environment.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LB-102 for the treatment of schizophrenia
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LB-102
Trial Overview
The study is testing the long-term safety and tolerability of LB-102, an investigational treatment for schizophrenia. All participants will receive LB-102 over a period of up to one year.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
An open label study
Find a Clinic Near You
Who Is Running the Clinical Trial?
LB Pharmaceuticals Inc.
Lead Sponsor
Citations
Antipsychotic Efficacy and Safety of LB-102 in the ...
In this phase 2 randomized clinical trial of participants with schizophrenia experiencing acute psychosis, 4-week treatment with once-daily LB- ...
Antipsychotic Efficacy and Safety of LB-102 in the Treatment of ...
In this phase 2 randomized clinical trial of participants with schizophrenia experiencing acute psychosis, 4-week treatment with once-daily LB- ...
3.
psychiatrictimes.com
psychiatrictimes.com/view/phase-2-trial-of-lb-102-for-schizophrenia-shows-positive-impact-on-cognitive-performancePhase 2 Trial of LB-102 for Schizophrenia Shows Positive ...
Schizophrenia/Psychosis. |. Drug Watch.
NCT07363577 | Study to Evaluate LB-102 for the ...
... Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia. Conditions. Schizophrenia. Schizophrenia. Schizophrenia.
Antipsychotic Efficacy and Safety of LB-102 in the ...
Objective: To evaluate the efficacy and safety of LB-102 in acute schizophrenia. ... Main outcomes and measures: The primary end point was ...
N-methyl amisulpride (LB-102) Clinical Study Report ...
... Safety, Tolerability, and. Pharmacokinetics of LB-102 Administered ... Schizophrenia. PHASE OF DEVELOPMENT: Phase 1. INVESTIGATIONAL SITES/LOCATIONS ...
7.
omnicuris.com
omnicuris.com/medshots/daily_updates/lb-102-efficacy-safety-acute-schizophrenia-trialLB-102 for Schizophrenia: Phase 2 Trial Results and ...
Efficacy of LB-102 for Schizophrenia Management. The study results were overwhelmingly positive as LB-102 met its primary endpoint.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.